Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Jan 7;16(1):e0244949. doi: 10.1371/journal.pone.0244949

Interleukin-18 and interferon-γ single nucleotide polymorphisms in Egyptian patients with tuberculosis

Noha A Hassuna 1,*, Mohamed El Feky 2, Aliae A R Mohamed Hussein 3, Manal A Mahmoud 3, Naglaa K Idriss 4, Sayed F Abdelwahab 1,5, Maggie A Ibrahim 2
Editor: Cinzia Ciccacci6
PMCID: PMC7790531  PMID: 33412574

Abstract

Background

Interleukin-18 (IL-18) and interferon-γ (IFN-γ) are cytokines of crucial role in inflammation and immune reactions. There is a growing evidence supporting important roles for IL-18 and IFN γ in tuberculosis (TB) infection and anti-tuberculosis immunity.

Objective

To evaluate the role of polymorphisms in IL-18-607 and -137 and INF-γ +874 in susceptibility to TB infection among Egyptian patients.

Methods

A case control study was conducted to investigate the polymorphism at IL-18-607, -137 and INF-γ+874 by sequence specific primer-polymerase chain reaction (SSP- PCR) in 105 patients with pulmonary and extra pulmonary tuberculosis and 106 controls.

Results

A significant protective effect against TB was found in homozygous CC genotype at IL-18 -137G/C, in addition to a 7-fold risk with GG and GC genotypes in the recessive model. Apart from a decreased risk with the AC genotype, no association was detected between the susceptibility to TB and different genotypes or alleles at the IL-18 -607A/C site. The homozygous AA genotype in INF-γ+874 showed a significant higher risk to TB than the homozygous TT or heterozygous AT genotypes with nearly a 2-fold risk of TB infection with the A allele. Regarding haplotype association, the GC haplotype was strongly associated with TB infection compared to other haplotypes.

Conclusion

These findings suggest; for the first time in Egypt; a significant risk to TB infection with SNP at the IL-18-137G/C with no LD with SNP at the IL-18-607 site. The homozygous AA genotype in INF-γ+874 showed a significant higher risk to TB than the homozygous TT or heterozygous AT genotypes.

Introduction

Tuberculosis (TB) is a notoriously infectious disease caused by Mycobacterium tuberculosis (MTB) [1]. A world-wide report estimated over 8.5 million TB cases distributed all over the world with the majority of cases in Africa and Asia [2]. Progression of TB occurs due to numerous reasons such as environmental factors, malnutrition, infection by human immune deficiency virus (HIV), immunosuppressive therapy and diabetes mellitus [3]. Despite the fact that over third of the world’s population is affected with TB, progression to active disease occurs only in 5–10% of these cases [3], which indicates the potentially major role of host genetic factors in the susceptibility to progression of TB. Several studies analyzed the relationship between various genetic variations and susceptibility to TB, particularly those in cytokine genes [46]. Cytokines play a significant role in host susceptibility and progression of TB. Interleukin -18 (IL-18), one of the IL-1 family members, is a pro-inflammatory cytokine with plays a vital role in the inflammatory cascade [7].

Production of IL-18 in response to mycobacterial antigens (Ags) is highly associated with IFN- γ production and with mycobacterial defensive immunity [8]. However, IL-18 levels were elevated in chronic refractory TB (CRTB) patients’ peripheral blood mononuclear cells as well as at the Tuberculous pleurisy (TBP) site, indicating a potential role for IL-18 in both protective immunity and human TB pathological responses [9]. The IL-18 gene is located on the long arm of chromosome 11 (11q22.2-q22.3) and incorporates many genetic polymorphisms, particularly in the promotor region.

The changes in IL-18 gene promotor have an influence on IL-18 development and operation. Two of the most common single nucleotide polymorphisms in IL-18 gene are located in the promoter region: -607C/A (rs1946518) and -137G/. C (rs187238) [10, 11]. Cloning and transcriptional research revealed that IL-18 expression was modified with these two polymorphisms. Nevertheless, studies done to investigate possible contribution of IL-18 polymorphisms to TB susceptibility have produced conflicting findings [11].

Interferon gamma (IFN- γ) is a key T-helper (Th) type -1 cytokine primarily produced by natural killer cells and T cells. It plays a crucial role in the activation of the macrophage to combat MTB infection [12].

A SNP (+874T/A; rs2430561) is found at the 50- end of a CA repeat at the first human IFN-γ intron.

The +874 T allele is linked to the 12 CA repeats, while the A allele is linked to the non-12 CA repeats. This leads to a change in IFN-γ expression as T allele is associated with a higher IFN-γ expression, while A allele is correlated with low expression [13].

Multiple studies investigated the association between IL-18 and INF γ polymorphisms and susceptibility to TB. However, consistent conclusions have not been reached, and single research is unable to determine combined effects. Furthermore, to the best of our knowledge there are no previous reports regarding IL-18 promotor SNP effect on the susceptibility to TB among Egyptian patients. Therefore, the aim of this study was to determine the association of (IL -18) and (INF-γ) polymorphisms ((-607C/A) and (-137G/C)) and (+874T/A); respectively and the risk of TB.

Patients and methods

Patients

This case-control study included 105 new tuberculous patients and 106 controls. Cases were enrolled from the tuberculosis outpatient clinic of Chest Department, Assiut University Hospital between December 2017, and May 2018. The study protocol was approved by the Local Ethics Committee (IRB no: 17300444) and was carried out in accordance with the Declaration of Helsinki. Written informed consents were obtained from all patients or those responsible for them.

Patients attending the outpatient tuberculosis clinic with newly diagnosed pulmonary and extrapulmonary TB were included. Pulmonary TB was confirmed by positive sputum smear and culture for MTB. Extra pulmonary TB was diagnosed by the presence of characteristic tuberculous granulomas composed of multinucleated giant cells, epithelioid cells and foamy cells surrounded by a rim of lymphocytes on histopathologic examination of biopsies from affected sites. Pott’s disease was diagnosed when magnetic resonance imaging (MRI) of the spines showed irregularity of both the endplate and anterior aspect of the vertebral bodies, with bone marrow edema and enhancement; T1: hypointense marrow in adjacent vertebrae, T2: hyperintense marrow, disc, soft tissue infection, T1 C+ (Gd): marrow, subligamentous, discal, dural enhancement [14].

Tuberculous Choroiditis was characterized by deep, multiple, discrete, yellowish lesions ranging from 0.5 to 3.0 mm in diameter [15].

HIV-positive subjects, previously treated TB cases, patients who did not regularly attend the scheduled clinic visits during the six months treatment period and patients who refused to participate were excluded from this study. Our sample is considered representative of a larger population.

Controls (n = 106) were age and sex matched participants from the same region and ethnic background with no history of previous or current TB infection.

All the patients received the following treatment:

First 2 months: Rifampicin 10 mg/kg, isoniazid 5 mg/kg, pyrazinamide (according to body weight range: 18.2–25 mg/kg for 40–55 kg body weight, 20–26.8 mg/kg for 56–75 kg and 22.2–26.3 mg/kg for 76–90 kg) and ethambutol (14.5–20 mg/kg for 40-55kg, 16–21.4 mg/kg for 56–75 kg and 17.8–21.1 mg/kg for 76-90kg). Then rifampicin and isoniazid are continued for 4 months.

Methods

Sampling and DNA extraction

Venous blood samples were collected from all study participants in EDTA-coated tubes (3–4 ml) and stored at -80°C for further use. Extraction of genomic DNA was done by standard chemical methods [16]. DNA efficiency and quantity were assessed via 0.8% agarose gel electrophoresis and by UV spectrophotometer. The extracted DNA was stored at -20°C for further SNP analysis.

SNP detection

Detection of IL-18 genetic polymorphisms. Sequence-specific primers PCR (SSP-PCR) method was used to detect the IL-18 -607C/A and IL-18-137G/C SNPs [17]. Briefly, a common reverse primer: (R): 5′-TAA CCT CAT TCA GGA CTT CC-3′, and two sequence-specific forward primers (F1): 5′-GTT GCA GAA AGTGTA AAA ATT ATT AC-3′ and (F2): 5′-GTT GCA GAA AGTGTA AAA ATT ATT AA-3′ were used for the IL-18 -607C/A SNP with a 196-bp fragment size. An internal positive control was added using a control forward primer: 5′-CTT TGC TAT CAT TCC AGG AA-3′ with a 301 bp fragment size.

Detection of the IL-18 -137G/C SNP was done using a common reverse primer (R): 5′-AGGAGG GCA AAATGC ACT GG-3′ and two sequence-specific forward primers (F1): 5′-CCC CAA CTT TTA CGG AAG AAAAG-3′ and (F2): 5′-CCC CAA CTT TTA CGG AAG AAA AC-3′ with a 261 bp fragment size. An internal positive control was added using control forward primer: 5′-CCA ATA GGA CTG ATT ATT CCG CA-3′ with a 446 bp fragment size.

For each position, three PCR reactions were carried out. Each reaction was performed in a total volume of 25 μL consisting of 12.5 μL MyTaq HS Red Master Mix (Bioline, USA Inc.),1 μL of each primer (the common reverse and either of the sequence-specific primers or the control primer), 30 ng genomic DNA, and nuclease-free water.

PCR conditions for IL-18-137G/C position were as follows: initial denaturation (4 min at 94°C), followed by 5 cycles (20 s at 94°C, 1 min at 68°C), and 25 cycles (20 s at 94°C, 40 s at 62°C and 40 s at 72°C).

PCR conditions for -607 position were as follows: initial denaturation (4 min at 94°C), followed by 7 cycles (20 s at 94°C, 40 s at 64°C, and 40 s at 72°C) and 35 cycles (20 s at 94°C, 40 s at 57°C and 40 s at 72°C). The product of each reaction mixture was evaluated by electrophoresis on 1% agarose gels.

Detection of IFN-γ genetic polymorphisms. Amplification refractory mutation system (ARMS) reaction was used to detect IFN-γ (+874T/A) SNP [18]. The following primers were used: A allele primer: 5-TTC TTA CAA CAC AAA ATC AAA TCA-3, T-allele primer:5-TTC TTA CAA CAC AAA ATC AAA TCT-3, Generic primer: 5- TCA ACA AAG CTG ATA CTC CA -3 with a 261 fragment. Successful PCR was checked by using human growth hormone internal control primers: forward primer: 5-GCC TTC CCA ACC ATT CCC TTA-3, reverse primer: 5-TCA CGG ATT TCT GTT GTG TTT C-3 with a 429 bp fragment.

For each sample two reactions were carried in 25 μL total volume with Master Mix, DNA as mentioned above except that each reaction contained specific primer mix (1 μL of one of the two allele-specific primers and 1 μL of the generic primer) and the internal control primers mix.

The PCR conditions were carried out as follows: 1 min at 95°C followed by 10 cycles (15 s at 95°C, 50 s at 65°C and 40 s at 72°C), then 20 cycles (20 s at 95°C, 50 s at 56°C and 50 s at 72°C). The PCR products were analyzed as mentioned above.

Statistical analysis

Data was collected and analyzed using SPSS (Statistical Package for the Social Science, version 20, IBM, and Armonk, New York). Continuous normally distributed variables were presented as means ± standard deviations, Student t-test was used to compare means. Test of significances: Chi square and Fisher Exact tests were used to compare the difference in distribution of frequencies among different groups. Multivariate logistic regression analysis was measured to examine the predictive power of the studied Cohort’s genotypes & Alleles (Odds Ratio -OR-, 95% confidence interval -95% CI- and Likelihood Ratio Test–LRT-Using the expectation maximization (EM) algorithm, the Haplo View program (version 4.2) was applied to estimate the haplotypes and the linkage disequilibrium (LD). P value <0.05 was considered statistically significant.

Results

This study included 105 TB patients: 64 females (60.9%) and 41 males (39.1%) with a mean age of 40.11 ± 16.15 years and 106 controls: 48 females (45.3%) and 58 (54.7%) males with a mean age of 37.65± 13.6. There were non-significant differences regarding demographic and clinical characteristics of the study participants as illustrated in Table 1. Pulmonary and extra pulmonary TB represented 70.5% and 29.5%, respectively, of the enrolled cases as shown in Table 2.

Table 1. Demographic and clinical characteristics of the study participants.

Variable Cases (n = 105) Controls (n = 106) P-value
Age (Mean ± SD, years) 40.1 ± 16.1 37.6± 13.6 0.4
Sex (N, %)
 Male 41 (39.0%) 48 (45.3%) 0.6
 Female 64 (60.9%) 58 (54.7%) 0.1
Smoking status
 Non-smoker (N, %) 82 (78.1%) 75 (70.8%) 0.1
 Ex-smoker (N, %) 21 (20.0%) 26 (24.5%) 0.8
 Current smoker (N, %) 2 (1.9%) 5 (4.7%) 0.2
Comorbidity
None 80 (76.1%) 78 (73.6%) 0.1
Pregnancy 1 (0.9%) 0 (0.0%) 0.1
HTN 13 (12.3%) 12 (11.3%) 1.0
Malignant mesothelioma 1 (0.9%) 0 (0.0%) 0.1
HCV 2 (1.9%) 1 (0.9%) 0.7
DM 9 (8.5%) 12 (1.3%) 0.4
Asthma 1 (0.9%) 0 (0.0%) 0.1
Ischemic heart disease 1 (0.9%) 3 (2.9%) 0.6

DM: Diabetes mellitus, HTN: Hypertension, HCV: Viral hepatitis C.

Table 2. Diagnosis of the included TB cases.

Diagnosis Frequency Percentage
*Pulmonary TB 74/105 70.5%
*Extra-pulmonary TB 31/105 29.5%
 TB pleural effusion 11/31 35.5%
 TB Lymphadenitis 5/31 16.1%
 TB choroiditis 1/31 3.2%
 TB pericardial effusion 2/31 6.5%
 Pott’s disease 1/31 3.2%
 TB ascites 2/31 6.5%
 TB cystitis 1/31 3.2%
 TB enteritis 3/31 9.7%
 TB mastitis 3/31 9.7%
 TB peritonitis 1/31 3.2%
 TB synovitis 1/31 3.2%

Polymorphisms and susceptibility to tuberculosis

Polymorphism at IL-18 -607C/A (rs1946518)

The observed genotype distribution of -607C/A SNP in control was not comparable to that predicted by HWE: the observed frequency of the AA genotype was 9 observed to 23.1, AC genotype was 81 observed compared to 52.7 expected and CC genotype was 16 observed compared to 30.1 expected (P = 0.0002). In addition, the observed distribution for the same SNP was not comparable in cases to that predicted by HWE: AA genotype was 13 observed to 18.8 expected, AC genotype was 63 observed compared to 51.2 expected and the CC genotype was 29 compared to 34.8 expected (P = 0.06).

The frequencies of AA, AC and CC genotypes at position -607C/A were 8.5%, 76.4% and 15.1%; respectively in controls, compared to 12.4%, 60%, 27.6%; respectively in cases with a significant decreased risk of TB with AC both as a genotype as well as in the dominant model (OR = 0.43, 95% CI 0.22–0.88, p = 0.015 and OR = 0.47, 95% CI 0.24–0.93, p = 0.026, respectively). The frequency of C-allele in controls and patients was 53.3% and 57.6%, respectively and were considered as reference group for regression analysis while the frequency of A-allele in controls and patients was 46.7% and 42.4%, respectively (Table 3), with no possible risk with either of the alleles per se.

Table 3. Genotypic & allelic frequencies of the studied cohort (cases vs. controls).
Case (n = 105) Control (n = 106) OR (95% CI) X2 P value
IL-18-607 C/A (rs1946518) Genotypes CC 29 (27.6%) 16 (15.1%) Reference
AC 63 (60%) 81 (76.4%) 0.43 (0.22–0.88) 5.88 0.015*
AA 13 (12.4%) 9 (8.5%) 0.8 (0.3–2.3) 0.18 0.671
Alleles C 121 (57.6%) 113 (53.3%) Reference
A 89 (42.4%) 99 (46.7%) 0.84 (0.57–1.23) 0.8 0.372
Dominant model CC 29 (27.6%) 16 (15.1%) Reference
AC + AA 76 (72.4%) 90 (84.9%) 0.47 (0.24–0.93) 4.93 0.026*
Recessive model AA 13 (12.4%) 9 (8.5%) Reference
AC+CC 92 (87.6%) 97 (91.5%) 0.66 (0.28–1.67) 0.85 0.355
IL-18-137 G/C (rs187238) Genotypes GG 56 (53.3%) 41 (38.7%) Reference
GC 40 (38.1%) 23 (21.7%) 1.27 (0.66–2.39) 0.53 0.467
CC 9 (8.6%) 42 (39.6%) 0.16 (0.07–0.37) 21.81 <0.001*
Alleles G 152 (72.4%) 105 (49.5%) Reference
C 58 (27.6%) 107 (50.5%) 0.37 (0.25–0.56) 23.14 <0.001*
Dominant model GG 56 (53.3%) 41 (38.7%) Reference
GC+CC 49 (46.7%) 65 (61.3%) 0.55 (0.32–0.95) 4.56 0.033*
Recessive model CC 9 (8.6%) 42 (39.6%) Reference
GC+GG 96 (91.4%) 64 (60.4%) 7 (3.27–15.58) 27.75 <0.001*
IFN-γ+874 T/A (rs2430561) Genotypes TT 16 (15.2%) 8 (7.5%) Reference
AT 60 (57.1%) 49 (46.2%) 0.61 (0.25–1.57) 1.09 0.298
AA 29 (27.6%) 49 (46.2%) 0.3 (0.11–0.74) 6.47 0.011*
Alleles T 118 (56.2%) 147 (69.3%) Reference
A 92 (43.8%) 65 (30.7%) 1.76 (1.19–2.63) 7.81 0.005*
Dominant model TT 29 (27.6%) 49 (46.2%) Reference
AT+AA 76 (72.4%) 57 (53.8%) 2.25 (1.58–4.01) 7.84 0.005*
Recessive model AA 16 (15.2%) 8 (7.5%) Reference
AT+TT 89 (84.8%) 98 (92.5%) 0.45 (0.19–1.09) 3.1 0.079

Polymorphism at IL-18 -137G/C (rs187238)

The observed genotype distribution of IL-18-137G/C SNP in control was not comparable to that predicted by HWE: the observed frequency of the CC genotype was 42 observed to 27, GC genotype was 23 observed compared to 53 expected and GG genotype was 41 observed compared to 26 expected (P = 0.003). On the other hand, the observed distribution for the same SNP was comparable in cases to that predicted by HWE: CC genotype was 9 observed to 8 expected, GC genotype was 40 observed compared to 41 expected and the GG genotype was 56 compared to 55 expected (P = 0.89). The frequencies of CC, GC and GG genotypes at position -137G/C were 39.6%, 21.7% and 38.7%; respectively in controls, compared to 8.6%, 38.1%, 53.3%; respectively. A strong protective effect against TB was observed with CC genotype (OR = 0.16, P<0.001) and the C allele (OR = 0.37, 95% CI 0.25–0.56), p<0.001) (Table 3). In addition, a 7-fold increased risk for TB was found in the recessive model in those having GG and GC genotypes (OR: 7(3.27–15.58), p<0.001).

Polymorphism at IFN-γ +874T/A (rs2430561)

The observed genotype distribution of +874T/A SNP in control was comparable to that predicted by HWE: the observed frequency of the AA genotype was 8 observed to 9.9, AT genotype was 49 observed compared to 45 expected and TT genotype was 49 observed compared to 40.9 expected (P = 0.67). Also, the observed distribution for the same SNP was comparable in cases to that predicted by HWE: AA genotype was 16 observed to 20.1 expected, AT genotype was 60 observed compared to 51.7 expected and the TT genotype was 29 compared to 33.1 expected (P = 0.26). The frequencies of AA, AT and TT genotypes at position +874T/A were 7.5%, 46.2%, 46.2%; respectively in control, compared to 15.2%, 68.9% and 27.6%; respectively in cases. The homozygous AA genotype showed a significant three-fold risk of TB infection and the heterozygous AT showed a significant two-fold risk (OR = 3.38, 95% CI 1.35–8.94, P = 0.01 and OR = 2.07, 95% CI 1.15–3.65, p = 0.016, respectively). Possession of the A allele was associated with increased risk of TB infection (OR = 1.76, 95% CI 1.19–2.63, P = 0.005) (Table 3).

Four different haplotypes existed (Fig 1a), where GC was the commonest haplotype in cases compared to healthy controls and was strongly correlated with TB susceptibility (X2:11.6, p<0.008). No LD was observed between the 2 SNP studied in IL-18 as D’ was 10 with r2 = 0.006 (Fig 1b).

Fig 1. Different haplotypes in rs1946518 rs187238 positions in IL-18 promotor a) Frequency of different haplotypes. b) Linkage equilibrium between the 2 SNPs in IL-18 (Haploview).

Fig 1

Discussion

Tuberculosis remains the world’s leading cause of mortality from infectious disease among adults, with more than 10 million newly diagnosed with tuberculosis each year. There is growing evidence suggesting an important role for inflammatory cytokines in the pathogenesis of TB [19, 20]. The presence of genotypic variations in different cytokines is known to be associated with increased susceptibility to TB infection [11, 21] and hence, recognizing the genetic factors influencing TB has increasingly attracted interest. A relation may occur when the polymorphism itself is functional and leads to altered susceptibility to the disease, or when an allele SNP is in LDS with an allele which is associate with disease susceptibility, or because of a conflicting effect induced by population. Genetic markers in human leukocyte antigen (HLA) and non-HLA genes such as toll-like receptors (TLRs), cytokine/chemokines and their receptors and vitamin D receptor (VDR) have been documented in studies to predict TB susceptibility [22]. In fact, several studies have shown that genetic variations in cytokines/chemokines genes are associated with susceptibility to as TB as IFN-γ [23], IL-12 [24], IL-10 [25], and others [26].

In this study, we explored for the first time the relationship between polymorphisms in 2 cytokine genes (IL-18 and IFN- γ) and susceptibility to TB among Egyptian patients in a case–control study, which is useful for detecting disease-associated gene polymorphism stratification.

Regarding the effect of IL-18 polymorphisms on TB infection, the results obtained by previous studies were contradictory.

In this study, we found no significant risk for TB with either of the homozygous genotypes, however; the heterozygous AC genotype was associated with a slightly lower risk for TB infection. This is partially consistent with previous studies reporting the lack of significant association between SNP at the Il-18-607 position and TB susceptibility [27, 28]. Furthermore, Zhen et al. [11] conducted a meta-analysis of five case-control studies, involving 1293 TB cases and 1724 healthy subjects for the IL-18 -607C/A polymorphism and found no association between this variant and TB susceptibility.

Notably, the C allele distribution in our cohort (57.6%) is similar to those among Chinese and a Brazilian cohorts [28, 29], however it is lower than that found among South India population and Iranian population [27, 30].

A high risk for TB was detected in the current study with GG and GC genotypes for IL-18-137G/C (rs187238) SNP with a protective effect of the CC genotype.

This finding is in agreement with the evidence that IL-18-137 C allele may be in favor of increased promoter activity of IL-18 gene, with an increased level of IL- 18, which is known to be associated with more robust TB resistance and lower TB susceptibility [31]. In addition, Shen et al. [32] conducted a meta-analysis for a total of 5 studies with 558 TB patient and 720 controls. The results showed that IL-18-137G/C polymorphisms in the IL-18 gene were associated with increased TB risk in china when comparing the G allele vs. C allele (OR = 1.49, 95% CI = 1.21–1.84, P = 0.0002, GG vs. GC+CC, P = 0.0003) [32]. Interestingly, the G allele frequency in our population (72.2%) was similar to Indian (76%) [30] and Brazilian population (74%) [29], but lower than Chinese (83%) [28]. The variability of the distribution of IL-18 genes SNP between various ethnicities and population groups could explain why populations from various races show heterogenous immune responses to TB and carry different susceptibilities. It is worth noting here to mention that we found no LD between the different haplotypes of the 2 SNP in IL-18 promotor. However, a significant association was found between the GC haplotype and susceptibility to TB infection. This haplotype could be reflected in the form of lower IL-18 production and more risk of TB development.

Furthermore, we found a significant role for the IFN-γ rs2430561 SNP in the susceptibility to TB. The homozygous AA genotype was associated with increased risk for TB infection and the A allele was found a strong risk factor as well.

These results are consistent with those found among Egyptian patients in a previous study, where the AA genotype was more frequent among TB patients [33]. Furthermore, other studies found a higher risk of TB in homozygous AA patients [34, 35]. These findings are explained by the lower IFN-γ in the AA genotype, since this SNP lies within the binding site of the NF-kappa-B transcription factor [36]. In addition, the increased frequency of AT among TB patients in our study was consistent with several studies carried on Caucasian and Asian ethnicities in USA, India, Brazil, Taiwan and China [3741].

Since the majority of TB infections were of the pulmonary type with a scarcity of extra pulmonary TB, studying the association between the affected system and different polymorphisms studied in this work was not possible.

Limitations

Although this study present for the first time in Egypt a possible association between IL-18-137G/C SNP and TB susceptibility, it still has some limitations like the relatively small sample size. In addition, the lack of cytokine levels measurement was not done, which was due to limited funding resources.

Conclusion

Our results denoted a potential association between IL-18-137G/C polymorphism and human susceptibility to TB. In addition, IFN-γ+874 AA genotype was found to deliberate a defensive effect. The mechanisms of how polymorphisms of IL-18 promotor site SNP influence its protein synthesis should be further studied.

Acknowledgments

Taif University Researchers Supporting Project number (TURSP-2020/51), Taif University, Taif, Saudi Arabia. Mohamed R Abdelrahman for revising the language of the manuscript.

Data Availability

All relevant data are within the paper.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Furin J, Cox H, Pai M. Tuberculosis. The Lancet. 2019;393(10181):1642–56. 10.1016/S0140-6736(19)30308-3 [DOI] [PubMed] [Google Scholar]
  • 2.Lv L, Li T, Xu K, Shi P, He B, Kong W, et al. Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis. Infection and Drug Resistance. 2018;11:147 10.2147/IDR.S153499 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clinical infectious diseases. 2012;54(6):784–91. 10.1093/cid/cir951 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Möller M, Hoal EG. Current findings, challenges and novel approaches in human genetic susceptibility to tuberculosis. Tuberculosis. 2010;90(2):71–83. 10.1016/j.tube.2010.02.002 [DOI] [PubMed] [Google Scholar]
  • 5.Laird S, Tuckerman E, Li T. Cytokine expression in the endometrium of women with implantation failure and recurrent miscarriage. Reproductive biomedicine online. 2006;13(1):13–23. 10.1016/s1472-6483(10)62011-1 [DOI] [PubMed] [Google Scholar]
  • 6.YIM JJ, Selvaraj P. Genetic susceptibility in tuberculosis. Respirology. 2010;15(2):241–56. 10.1111/j.1440-1843.2009.01690.x [DOI] [PubMed] [Google Scholar]
  • 7.Chang JT, Segal BM, Nakanishi K, Okamura H, Shevach EM. The costimulatory effect of IL-18 on the induction of antigen-specific IFN-γ production by resting T cells is IL-12 dependent and is mediated by up-regulation of the IL-12 receptor β2 subunit. European journal of immunology. 2000;30(4):1113–9. [DOI] [PubMed] [Google Scholar]
  • 8.Lee SH, Choi I, Jeon Y, Park S, Lee H, Lee Y, et al. Association between the interleukin-18 promoter polymorphism and pulmonary tuberculosis in a Korean population. The International journal of tuberculosis and lung disease. 2011;15(9):1246–51. 10.5588/ijtld.11.0031 [DOI] [PubMed] [Google Scholar]
  • 9.Song CH, Lee JS, Nam HH, Kim JM, Suhr JW, Jung SS, et al. IL-18 production in human pulmonary and pleural tuberculosis. Scandinavian journal of immunology. 2002;56(6):611–8. 10.1046/j.1365-3083.2002.01143.x [DOI] [PubMed] [Google Scholar]
  • 10.Pavlovna KO, Sergeevna SN, Anatolievna LJ, Ivanovich KJ, Leonidovich FM, Alexandrovich KE, et al. Association of single nucleotide polymorphisms in the IL-18 gene with production of IL-18 protein by mononuclear cells from healthy donors. Mediators of inflammation. 2008;2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Zhen L-B, Sun Y-P, Chen Y-Y, Yin L-S. IL-18 polymorphisms and tuberculosis susceptibility: a meta-analysis. African health sciences. 2019;19(1):1311–20. 10.4314/ahs.v19i1.2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Collins HL, Kaufmann SH. The many faces of host responses to tuberculosis. Immunology. 2001;103(1):1 10.1046/j.1365-2567.2001.01236.x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Pravica V, Perrey C, Stevens A, Lee J-H, Hutchinson IV. A single nucleotide polymorphism in the first intron of the human IFN-γ gene:: Absolute correlation with a polymorphic CA microsatellite marker of high IFN-γ production. Human immunology. 2000;61(9):863–6. 10.1016/s0198-8859(00)00167-1 [DOI] [PubMed] [Google Scholar]
  • 14.Thammaroj J, Kitkuandee A, Sawanyawisuth K. Differences of Mri features between tuberculous and bacterial spondylitis in a Tb-endemic area. Southeast Asian Journal of Tropical Medicine and Public Health. 2015;46(1):71. [PubMed] [Google Scholar]
  • 15.BCSC. Intraocular Inflammation and Uveitis. Infectious uveitis. San Francisco: American Academy of Opthalmology; 2009–2010; 223–292.
  • 16.Subbarayan PR, Sarkar M, Ardalan B. Isolation of genomic DNA from human whole blood. Biotechniques. 2002;33(6):1231–4. 10.2144/02336bm10 [DOI] [PubMed] [Google Scholar]
  • 17.Asefi V, Mojtahedi Z, Khademi B, Naeimi S, Ghaderi A. Head and neck squamous cell carcinoma is not associated with interleukin-18 promoter gene polymorphisms: a case-control study. The Journal of Laryngology and Otology. 2009;123(4):444 10.1017/S0022215108003733 [DOI] [PubMed] [Google Scholar]
  • 18.Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV. ARMS-PCR methodologies to determine IL-10, TNF-α, TNF-β and TGF-β1 gene polymorphisms. Transplant immunology. 1999;2(7):127–8. [DOI] [PubMed] [Google Scholar]
  • 19.O’Garra A, Redford PS, McNab FW, Bloom CI, Wilkinson RJ, Berry MP. The immune response in tuberculosis. Annual review of immunology. 2013;31:475–527. 10.1146/annurev-immunol-032712-095939 [DOI] [PubMed] [Google Scholar]
  • 20.Kumar NP, Moideen K, Banurekha VV, Nair D, Babu S. Plasma proinflammatory cytokines are markers of disease severity and bacterial burden in pulmonary tuberculosis Open forum infectious diseases: Oxford University Press US; 2019. p. ofz257 10.1093/ofid/ofz257 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Wu S, Wang Y, Zhang M, Wang M, He J-Q. Genetic variants in IFNG and IFNGR1 and tuberculosis susceptibility. Cytokine. 2019;123:154775 10.1016/j.cyto.2019.154775 [DOI] [PubMed] [Google Scholar]
  • 22.Harishankar M, Selvaraj P, Bethunaickan R. Influence of Genetic Polymorphism Towards Pulmonary Tuberculosis Susceptibility. Frontiers in medicine. 2018;5:213-. 10.3389/fmed.2018.00213 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Ansari A, Talat N, Jamil B, Hasan Z, Razzaki T, Dawood G, et al. Cytokine gene polymorphisms across tuberculosis clinical spectrum in Pakistani patients. PloS one. 2009;4(3):e4778 10.1371/journal.pone.0004778 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Morris GA, Edwards DRV, Hill PC, Wejse C, Bisseye C, Olesen R, et al. Interleukin 12B (IL12B) genetic variation and pulmonary tuberculosis: a study of cohorts from The Gambia, Guinea-Bissau, United States and Argentina. PloS one. 2011;6(2):e16656 10.1371/journal.pone.0016656 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Meenakshi P, Ramya S, Shruthi T, Lavanya J, Mohammed H, Mohammed S, et al. Association of IL-1β+ 3954 C/T and IL-10-1082 G/A cytokine gene polymorphisms with susceptibility to tuberculosis. Scandinavian journal of immunology. 2013;78(1):92–7. 10.1111/sji.12055 [DOI] [PubMed] [Google Scholar]
  • 26.Wu S, Wang M-G, Wang Y, He J-Q. Polymorphisms of cytokine genes and tuberculosis in two independent studies. Scientific Reports. 2019;9 10.1038/s41598-019-39249-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Taheri M, Hashemi-Shahri S, Hamzehnejadi M, Naderi M, Moazeni-Roodi A, Bahari G, et al. Lack of association between interleukin-18-607 C/A gene polymorphism and pulmonary tuberculosis in Zahedan, Southeast Iran. Prague Med Rep. 2012;113(1):16–22. 10.14712/23362936.2015.33 [DOI] [PubMed] [Google Scholar]
  • 28.Zhou C, Ouyang N, Li QH, Luo SX, He Q, Lei H, et al. The-137G/C single nucleotide polymorphism in IL-18 gene promoter contributes to tuberculosis susceptibility in Chinese Han population. Infection, Genetics and Evolution. 2015;36:376–80. 10.1016/j.meegid.2015.10.014 [DOI] [PubMed] [Google Scholar]
  • 29.Segat L, Bevilacqua D, Boniotto M, Arraes LC, De Souza PR, de Lima Filho JL, et al. IL-18 gene promoter polymorphism is involved in HIV-1 infection in a Brazilian pediatric population. Immunogenetics. 2006;58(5–6):471–3. 10.1007/s00251-006-0104-7 [DOI] [PubMed] [Google Scholar]
  • 30.Harishankar M, Selvaraj P, Rajeswari D, Anand S, Narayanan P. Promoter polymorphism of IL-18 gene in pulmonary tuberculosis in South Indian population. International journal of immunogenetics. 2007;34(5):317–20. 10.1111/j.1744-313X.2007.00714.x [DOI] [PubMed] [Google Scholar]
  • 31.Giedraitis V, He B, Huang W-X, Hillert J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. Journal of neuroimmunology. 2001;112(1–2):146–52. 10.1016/s0165-5728(00)00407-0 [DOI] [PubMed] [Google Scholar]
  • 32.Shen L, Liang Z, Xu C, Yang J, Han X, Zhao H, et al. Association between Interleukin-18-137G/C Gene Polymorphisms and TuberculosisRisk in Chinese Population: A Meta-Analysis. J Clin Cell Immunol. 2017;8(4):514. [Google Scholar]
  • 33.Mosaad Y, Soliman O, Tawhid Z, Sherif D. Interferon-gamma+ 874 T/A and interleukin-10-1082 A/G single nucleotide polymorphism in Egyptian children with tuberculosis. Scandinavian journal of immunology. 2010;72(4):358–64. 10.1111/j.1365-3083.2010.02426.x [DOI] [PubMed] [Google Scholar]
  • 34.Selma WB, Harizi H, Bougmiza I, Hannachi N, Kahla IB, Zaieni R, et al. Interferon gamma+ 874T/A polymorphism is associated with susceptibility to active pulmonary tuberculosis development in Tunisian patients. DNA and cell biology. 2011;30(6):379–87. 10.1089/dna.2010.1157 [DOI] [PubMed] [Google Scholar]
  • 35.Onay H, Ekmekci A, Durmaz B, Sayin E, Cosar H, Bayram N, et al. Interferon-γ gene and interferon-γ receptor-1 gene polymorphisms in children with tuberculosis from Turkey. Scandinavian journal of infectious diseases. 2010;42(1):39–42. 10.3109/00365540903253502 [DOI] [PubMed] [Google Scholar]
  • 36.Rossouw M, Nel HJ, Cooke GS, van Helden PD, Hoal EG. Association between tuberculosis and a polymorphic NFκB binding site in the interferon γ gene. The lancet. 2003;361(9372):1871–2. 10.1016/S0140-6736(03)13491-5 [DOI] [PubMed] [Google Scholar]
  • 37.Moran A, Ma X, Reich R, Graviss E. No association between the+ 874T/A single nucleotide polymorphism in the IFN-γ gene and susceptibility to TB. The International Journal of Tuberculosis and Lung Disease. 2007;11(1):113–5. [PubMed] [Google Scholar]
  • 38.Gutlapalli V, Sykam A, Tenali SP, Suneetha S, Suneetha LM. High levels of plasma interferon gamma and+ 874T/A gene polymorphism is associated with HIV-TB co-infection. Human immunology. 2016;77(12):1264–70. 10.1016/j.humimm.2016.08.001 [DOI] [PubMed] [Google Scholar]
  • 39.Leandro AC, Rocha MA, Lamoglia-Souza A, VandeBerg JL, Cavalcanti Rolla V, Bonecini-Almeida MdG. No association of IFNG+ 874T/A SNP and NOS2A-954G/C SNP variants with nitric oxide radical serum levels or susceptibility to tuberculosis in a Brazilian population subset. BioMed research international. 2013;2013 10.1155/2013/901740 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Lee S-W, Chuang T-Y, Huang H-H, Lee K-F Chen TT-W, Kao Y-H, et al. Interferon gamma polymorphisms associated with susceptibility to tuberculosis in a Han Taiwanese population. Journal of Microbiology, Immunology and Infection. 2015;48(4):376–80. [DOI] [PubMed] [Google Scholar]
  • 41.Shen C, Jiao W-W, Feng W-X, Wu X-R, Xiao J, Miao Q, et al. IFNG polymorphisms are associated with tuberculosis in Han Chinese pediatric female population. Molecular biology reports. 2013;40(9):5477–82. 10.1007/s11033-013-2647-7 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Cinzia Ciccacci

26 Oct 2020

PONE-D-20-27317

Interleukin-18 and Interferon-γ Single Nucleotide Polymorphisms in Egyptian patients with Tuberculosis.

PLOS ONE

Dear Dr. Hassuna,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Specifically, the Authors should revise the manuscript with particular focus on the methods section, as requested by Reviewer2.

Please submit your revised manuscript by Nov 27 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Cinzia Ciccacci

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants.

Please ensure you have provided sufficient details to replicate the analyses such as:

a) a description of any inclusion/exclusion criteria that were applied to participant recruitment,

b) a statement as to whether your sample can be considered representative of a larger population, and

c) a description of how participants were recruited.

3. Thank you for stating in the text of your manuscript "Written informed consents were obtained from all patients or those responsible for them."

Please also add this information to your ethics statement in the online submission form.

4. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: No

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The work deals with an essential subject of infectious diseases, including tuberculosis.

However, it needs to be revised again:

1. the linguistic correctness and clarity of the document should be checked

2. the text should be stylistically uniform and adapted to the requirements of the journal

2. it is necessary to harmonize the writing of genes with or without information on pairs of alleles

3. in the text, spaces separating numerical values from units are missing several times

4. the storage temperature of the samples should be verified

5. in the description of the results, double brackets appear several times, with no justification

6. in Table 1, the number of decimal places should be standardized

7. discussion should be enriched with additional publications analyzing SNP polymorphism in tuberculosis

Reviewer #2: - Studies on the role of genetics in the pathogenesis of susceptibility to TB disease is always interesting. In this study, authors objective is to find whether there in an association between SNP-607 C/A and -137 G/C in IL-18 gene and also SNP +874 A/T IFN-gamma gene with susceptibility to TB both pulmonary and extrapulmonary in the Egyptian population. There is no clarity regarding this matter yet. Various studies and meta-analyzes with populations from different countries, races and ethnicities show inconclusive results, although most of the results show no association. This study is quite interesting because it is the first study conducted in Egyptian and the results show that there is an association at least between SNP -137 G / C of IL-18 gene and susceptibility to suffer from TB. I have a few questions and comments as follows:

- Abstract section

o To emphasize the importance of this study, it will be better if a background subheading added in the abstract

o In methods section the study design must be mention

o There are inconsistency in conclusion, authors was not mention association between SNP in IFN gamma and TB susceptibility, while it was appear in objective and result, meanwhile authors draw a conclusion on possible association these SNPs and the development of drug resistance which was not appear in objective section and also was not back up by data in abstract results section

- Methods section

o How authors define cases? How do they diagnose pulmonary and extra pulmonary TB?

o How about inclusion criteria? is it only new TB cases or previously treated TB cases also enrolled in the study?

o How the authors define control? It was not written in the manuscript

o Authors also should explain on how matching process was done or was not done

- Results section

o Table 1 only showed basic characteristic of cases but not controls. The data is important to show the homogeneity between cases and controls. It might be possible that the difference in basic characteristics such as comorbidities between groups that increasing the susceptibility to TB

o The OR in table 2, is it adjusted or crude OR?

o Page 12 last paragraph. How drug resistance determined? Authors should also notify this in the method section

- There were several typos on write SNP, please make appropriate correction

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Jan 7;16(1):e0244949. doi: 10.1371/journal.pone.0244949.r002

Author response to Decision Letter 0


1 Dec 2020

Dear Professors,

We would like to thank you for your valuable comments that greatly improved the overall quality of our manuscript entitled “Interleukin-18 & Interferon-γ Single Nucleotide Polymorphisms in Egyptian patients with Tuberculosis.”. We are enclosing the revised manuscript with the changes tracked and highlighted (yellow) in the text. Also, comments raised by the reviewers (in italics) are outlined below, followed by our detailed responses (in regular blue font).

Reviewer #1:

Comment 1: The linguistic correctness and clarity of the document should be checked

Response to comment 1: We would like to thank you for this comment. The linguistic correctness and clarity were revised.

Comment 2: The text should be stylistically uniform and adapted to the requirements of the journal

Response to comment 2:

Thank you for this comment. The manuscript is now stylistically uniform as per the journal’s requirements.

Comment 3: It is necessary to harmonize the writing of genes with or without information on pairs of alleles.

Response to comment 3: As recommended by the reviewer, the writing of alleles is now harmonized.

Comment 4: In the text, spaces separating numerical values from units are missing several times.

Response to comment 4: Thank you for pointing this out. Corrections are now done.

Comment 5: The storage temperature of the samples should be verified

Response to comment 5: We appreciate this comment. The temperature is now corrected.

Comment 6: In the description of the results, double brackets appear several times, with no justification.

Response to comment 6: We thank you for this comment. Corrections are now done.

Comment 7: In Table 1, the number of decimal places should be standardized

Response to comment 7: Thank you for this comment. Decimals are fixed.

Comment 8: Discussion should be enriched with additional publications analyzing SNP polymorphism in tuberculosis.

Response to comment 8: We appreciate this comment that enriched the discussion. Additional publications regarding other SNPs are now added.

Reviewer #2:

Abstract section

Comment 1: To emphasize the importance of this study, it will be better if a background subheading added in the abstract.

Response to comment 1: We would like to thank the reviewer for this comment. A background sub-heading is now added to the abstract.

Comment 2: In methods section the study design must be mention

Response to comment 2: Thank you for this comment. Study design is added to the methods section.

Comment 3: There are inconsistency in conclusion, authors was not mention association between SNP in IFN gamma and TB susceptibility, while it was appear in objective and result, meanwhile authors draw a conclusion on possible association these SNPs and the development of drug resistance which was not appear in objective section and also was not back up by data in abstract results section.

Response to comment 3: We apologize for this inconsistency.

Regarding the SNP in IFNg: we now pointed to its effect in the conclusion section. Regarding the association of these SNPs and the development of drug resistance: we agree with the reviewer and thus we removed this from the conclusion due to the small number of resistant cases detected in this study.

Methods section

Comment 4: How authors define cases? How do they diagnose pulmonary and extra pulmonary TB?

Response to comment 4: Thank you for bringing this crucial point up. Definition of cases and methods of diagnosis of pulmonary and extra pulmonary cases were added to Methods section.

Comment 5: How about inclusion criteria? is it only new TB cases or previously treated TB cases also enrolled in the study?

Response to comment 5: We appreciate this comment. Inclusion criteria were mentioned in the Methods section. "Only newly diagnosed TB cases were included in the study" this was added to the Methods section.

Comment 6: How the authors define control? It was not written in the manuscript.

Response to comment 6: Thank you for this comment. Definition of controls was mentioned in the Methods section.

Comment 7: Authors also should explain on how matching process was done or was not done.

Response to comment 7: Thank you for this comment. Matching was done for age and sex and this is now added in the Methods Section.

Results section

Comment 8: Table 1 only showed basic characteristic of cases but not controls. The data is important to show the homogeneity between cases and controls. It might be possible that the difference in basic characteristics such as comorbidities between groups that increasing the susceptibility to TB

Response to comment 8: We appreciate this comment that helped us to better present our data. Demographic characteristics of controls are added and compared to those of cases with estimation of the presence of statistically significant differences.

Comment 9: The OR in table 2, is it adjusted or crude OR?

Response to comment 9: Thank you for this comment. The used OR is crude OR.

Comment 10: Page 12 last paragraph. How drug resistance determined? Authors should also notify this in the method section.

Response to comment 10: Thank you for this comment. We removed data regarding resistance due to the very small (non-significant) number of resistant cases.

Comment 11: There were several typos on write SNP, please make appropriate correction.

Response to comment 11: Thank you for this comment. Typing errors were corrected.

Decision Letter 1

Cinzia Ciccacci

21 Dec 2020

Interleukin-18 and Interferon-γ Single Nucleotide Polymorphisms in Egyptian patients with Tuberculosis.

PONE-D-20-27317R1

Dear Dr. Hassuna,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Cinzia Ciccacci

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #2: (No Response)

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #2: (No Response)

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: (No Response)

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #2: (No Response)

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #2: (No Response)

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #2: No

Acceptance letter

Cinzia Ciccacci

28 Dec 2020

PONE-D-20-27317R1

Interleukin-18 and Interferon-γ Single Nucleotide Polymorphisms in Egyptian patients with Tuberculosis

Dear Dr. Hassuna:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Cinzia Ciccacci

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Data Availability Statement

    All relevant data are within the paper.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES